Nuclear factor-κB is central to the expression of truncated neurokinin-1 receptor in breast cancer: Implication for breast cancer cell quiescence within bone marrow stroma

Cancer Research

Volumn 67, Issue 4, 2007, Pages 1653-1659

  Ramkissoon, Shakti H ^a   Patel, Prem S ^b   Taborga, Marcelo ^a   Rameshwar, Pranela ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; NEUROKININ 1 RECEPTOR;

ARTICLE; BONE MARROW CELL; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA FLANKING REGION; DOWN REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; NORTHERN BLOTTING; PRIORITY JOURNAL; STROMA; TISSUE SPECIFICITY; WESTERN BLOTTING; BIOSYNTHESIS; BREAST TUMOR; CELL COMMUNICATION; COCULTURE; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; STROMA CELL; TUMOR CELL LINE;

BONE MARROW CELLS; BREAST NEOPLASMS; CELL COMMUNICATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DOWN-REGULATION; HUMANS; NF-KAPPA B; RECEPTORS, NEUROKININ-1; STROMAL CELLS; TRANSFECTION;

EID: 33847755010     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3813     Document Type: Article

References (35)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Mundy GR. Metastasis to bone: causes, consequences, and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
3. Wicha MS. Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res 2006;12:5606-7.
4. Moharita A, Taborga M, Corcoran K, Bryan M, Patel P, Rameshwar P. SDF-1α regulation in breast cancer cells contacting bone marrow stroma is critical for normal hematopoiesis. Blood 2006;108:3245-52.
5. Singh D, Joshi DD, Hameed M, et al. Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells. Implications for bone marrow metastasis. Proc Natl Acad Sci U S A 2000;97:388-93.
6. Grotzer MA, Janss AJ, Fung K, et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 2000;18:1027-35.
7. Winkler A, Papsdorf G, Odarjuk J, Siems WE, Fickel J, Melzig MF. Expression and characterization of the substance P (NK1) receptor in the rat pituitary and AtT20 mouse pituitary tumor cells. Eur J Pharmacol 1995;291:51-5.
8. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localization and therapy with radiopeptides. Curr Med Chem 2000;7:971-94.
9. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 1995;61:786-92.
10. Rameshwar P, Oh HS, Yook C, Gascon P, Chang VT. Substance P-fibronectin-cytokine interactions in myeloproliferative disorders with bone marrow fibrosis. Acta Haematol 2003;109:1-10.
11. Quartara L, Maggi CA. The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation. Neuropeptides 1997;31:537-63.
12. Friess H, Zhu Z, Liard V, et al. Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest 2003;83:731-42.
13. Palma C, Maggi CA. The role of tachykinins via NK1 receptors in progression of human gliomas. Life Sci 2000;67:985-1001.
14. Reubi JC, Zimmermann A, Jonas S, et al. Regulatory peptide receptors in human hepatocellular carcinomas. Gut 1999;45:766-74.
15. Reubi JC, Mazzucchelli L, Hennig I, Laissue JA. Local up-regulation of neuropeptide receptors in host blood vessels around human colorectal cancers. Gastroenterology 1996;110:1719-26.
16. Theodorsson-Norheim E, Jornvall H, Andersson M, Norheim I, Oberg K, Jacobsson G. Isolation and characterization of neurokinin A, neurokinin A(3-10), and neurokinin A(4-10) from a neutral water extract of a metastatic ileal carcinoid tumour. Eur J Biochem 1987;166:693-7.
17. Bandari PS, Qian J, Oh HS, et al. Crosstalk between neurokinin receptors is relevant to hematopoietic regulation: cloning and characterization of neurokinin-2 promoter. J Neuroimmunol 2003;138:65-75.
18. Rameshwar P, Poddar A, Gascón P. Hematopoietic regulation mediated by interactions among the neurokinins and cytokines. Leuk Lymphoma 1997;28:1-10.
19. Fong TM, Anderson SA, Yu H, Huang RR, Strader CD. Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. Mol Pharmacol 1992;41:24-30.
20. Bandari PS, Qian J, Yehia G, et al. Differences in the expression of neurokinin receptor in neural and bone marrow mesenchymal cells: implications for neuronal expansion from bone marrow cells. Neuropeptides 2002;36:13-21.
21. Patel HJ, Ramkissoon SH, Patel PS, Rameshwar P. Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides. Proc Natl Acad Sci U S A 2005;102:17436-41.
22. Rao G, Patel PS, Idler SP, et al. Facilitating role of preprotachykinin-I gene in the integration of breast cancer cells within the stromal compartment of the bone marrow: a model of early cancer progression. Cancer Res 2004;64:2874-81.
23. Greco SJ, Corcoran KE, Cho KJ, Rameshwar P. Tachykinins in the emerging immune system: relevance to bone marrow homeostasis and maintenance of hematopoietic stem cells. Front Biosci 2004;9:1782-93.
24. Corcoran KE, Patel PS, Rameshwar P. An in vitro method to select malignant cells from surgical biopsies of breast cancer patients. Biol Proced Online 2005;7:8-16.
25. Ramkissoon SH, Patel HJ, Taborga M, Rameshwar P. G protein-coupled receptors in haematopoietic disruption. Expert Opin Biol Ther 2006;6:109-20.
26. Bours V, Bentires-Alj M, Hellin AC, et al. Nuclear factor-κB, cancer, and apoptosis. Biochem Pharmacol 2000;60:1085-9.
27. Mori N, Fujii M, Ikeda S, et al. Constitutive activation of NF-κB in primary adult T-cell leukemia cells. Blood 1999;93:2360-8.
28. Higgins KA, Perez JR, Coleman TA, et al. Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and cases tumor regression. Proc Natl Acad Sci U S A 1993;90:9901-5.
29. Baeuerle PA. Pro-inflammatory signaling: last pieces in the NF-κB puzzle? Curr Biol 1998;8:R19-22.
30. Freireich EJ, Kuzrock R, Estrov Z. Metastasis - an alternative hypothesis. Cancer 2005;103:1537-9.
31. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. In press 2006.
32. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006;355:1253-61.
33. Chan JL, Tang KC, Patel AP, et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-γ. Blood 2006;107:4817-24.
34. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigen and recall antigens. J Immunol 2003;171:3426-34.
35. Palma C. Tachykinins and their receptors in human malignancies. Curr Drug Targets 2006;7:1043-52.